# EDGAR Filing Document

**Accession Number:** 0001840199
**File Stem:** 0001840199-26-000054
**Filing Date:** 2026-4
**Character Count:** 6134
**Document Hash:** 0bf4e02d1823def6d14468a778553699
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001840199-26-000054.hdr.sgml**: 20260428

**ACCESSION NUMBER**: 0001840199-26-000054

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20260428

**FILED AS OF DATE**: 20260428

**DATE AS OF CHANGE**: 20260428

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Waldencast plc
- **CENTRAL INDEX KEY:** 0001840199
- **STANDARD INDUSTRIAL CLASSIFICATION:** PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40207
- **FILM NUMBER:** 26909474

**BUSINESS ADDRESS:**
- **STREET 1:** 81 FULHAM ROAD
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** SW3 6RD
- **BUSINESS PHONE:** 44 (0)20 3196 0264

**MAIL ADDRESS:**
- **STREET 1:** 81 FULHAM ROAD
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** SW3 6RD

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Waldencast Acquisition Corp.
- **DATE OF NAME CHANGE:** 20210112

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER** 

**PURSUANT TO RULE 13a-16 or 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the Month of: April 2026

Commission File Number: 001-40207

**Waldencast plc**

(Translation of Registrant's name into English)

**81 Fulham Road**

**London, SW3 6RD**

**United Kingdom**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

------

**Press Release**

On April 28, 2026, Waldencast plc issued a press release, a copy of which is attached hereto as Exhibit 99.1 to this Form 6-K.

The information in this report on Form 6-K (including Exhibit 99.1 hereto) (the "Report") shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

**EXHIBIT INDEX**

EXHIBIT NO. DESCRIPTION <br> 99.1 <u>[Press release of Waldencast plc, dated April 28, 2026](pr-termofsecinvestigationx.htm)</u>

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | Waldencast plc | Waldencast plc |
| | | (Registrant) | (Registrant) |
| Date: April 28, 2026 | By: | /s/ Michel Brousset | /s/ Michel Brousset |
|  |  | Name: | Michel Brousset |
|  |  | Title: | Chief Executive Officer |

---

## Exhibit 99.1

**<u>Exhibit 99.1</u>**

![image_0.jpg](image_0.jpg)

**Waldencast announces conclusion of SEC investigation**

April 28, 2026

LONDON, April 28, 2026 (GLOBE NEWSWIRE) – Waldencast plc (NASDAQ: WALD) ("Waldencast" or the "Company"), a global multi-brand beauty and wellness platform, announced today that it was notified by the staff of the U.S. Securities and Exchange Commission (the "SEC") that they have concluded their investigation of the Company relating to Waldencast's restatement of its financial results and material weaknesses in its internal control over financial reporting related to historical accounting practices used by Obagi Cosmeceuticals (the "Investigation") and, based on the information available as of the date of the notice, the SEC does not intend to recommend an enforcement action against Waldencast.

"We are pleased with the favorable outcome of the SEC's investigation." stated Michel Brousset, Chief Executive Officer of Waldencast. "Throughout the Investigation, we fully cooperated and dedicated significant resources to the process. At the same time, we maintained our focus on executing our business plans, upholding strong governance, and ensuring robust internal controls."

The Investigation was previously disclosed by the Company in its periodic reports under the Securities Exchange Act of 1934, as amended. As previously disclosed, the Company voluntarily contacted the SEC regarding these matters and has fully cooperated with the SEC throughout the course of the Investigation, incurring substantial legal, advisory and other related costs.

**About Waldencast plc**

Founded by Michel Brousset and Hind Sebti, Waldencast's ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast's vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand's distinct DNA. For more information please visit: https://ir.waldencast.com.

Obagi Medical is an industry-leading, advanced skin care line rooted in research and skin biology, refined with a legacy of over 35 years' experience. Obagi Medical products are designed to address the appearance of premature aging, photodamage, skin discoloration, acne, and sun damage. More information about Obagi Medical is available on the brand's website at www.obagi.com.

Founded in 2016, Milk Makeup quickly became a cult-favorite among the beauty community for its values of self-expression and inclusion, captured by its signature "Live Your Look", its innovative formulas, and clean ingredients. The brand creates vegan, cruelty-free, clean formulas and has its Milk Makeup HQ in Downtown NYC. More information about Milk Makeup is available on the brand's website at www.milkmakeup.com.

Contacts:

**Investors**<br>ICR<br>Allison Malkin<br>waldencastir@icrinc.com

**Media**<br>ICR

&nbsp;&nbsp;&nbsp;&nbsp;

------

<br>Brittney Fraser/Alecia Pulman<br>waldencast@icrinc.com

&nbsp;&nbsp;&nbsp;&nbsp;